Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme

BACKGROUND: The recent failure of checkpoint-blockade therapies for glioblastoma multiforme (GBM) in late-phase clinical trials has directed interest toward adoptive cellular therapies (ACTs). In this open-label, first-in-human trial, we have assessed the safety and therapeutic potential of cytomega...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Smith, Corey, Lineburg, Katie E., Martins, J. Paulo, Ambalathingal, George R., Neller, Michelle A., Morrison, Beth, Matthews, Katherine K., Rehan, Sweera, Crooks, Pauline, Panikkar, Archana, Beagley, Leone, Le Texier, Laetitia, Srihari, Sriganesh, Walker, David, Khanna, Rajiv
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2020
Assuntos:
Clinical Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7598048/
https://ncbi.nlm.nih.gov/pubmed/32750039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI138649
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados